Breaking News

Fujifilm Invests $200M to Expand Cell Therapy Capabilities

New site will include iPSC manufacturing for R&D applications for drug discovery, drug efficacy, and pharmacology.

FUJIFILM Corporation has invested $200 million in two subsidiaries to expand global cell therapy contract development and manufacturing (CDMO) capabilities.  The investment is earmarked for both the new headquarters of FUJIFILM Cellular Dynamics, Inc., a global developer, and manufacturer of human induced pluripotent stem cells (iPSC) and iPSC-derived cells, and the California site of FUJIFILM Diosynth Biotechnologies, a biologics and advanced therapies CDMO. The investment will strengthen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters